Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of CellSeed Inc.. A complete text table follows the diagram.
Laboratory consumables supplied 95% of sales, but JPY451 million of R&D went into cell-sheet regenerative medicine.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Laboratory Consumable Equipment | 1 | 35.1M | 94.9% of reported total |
| Cell-Sheet Regenerative Medicine | 1 | 1.9M | 5.1% of reported total |
| Revenues From External Customers | 2 | 37M | Reported six-month total · ¥37M |
| Operating loss | 2 | 623M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 660M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Laboratory Consumable Equipment | Revenues From External Customers | 35.1M |
| Cell-Sheet Regenerative Medicine | Revenues From External Customers | 1.9M |
| Revenues From External Customers | Operating costs & expenses | 37M |
| Operating loss | Operating costs & expenses | 623M |